Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: A meta-analysis of randomized controlled and open-label trials

Journal of Clinical Psychopharmacology

Volumn 31, Issue 5, 2011, Pages 613-624

  Vita, Antonio ^a,b   De Peri, Luca ^a   Sacchetti, Emilio ^a,b,c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Spedali Civili Hospital   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

anticonvulsants; antidepressants; antipsychotics; Borderline personality disorder; meta analysis; placebo

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; NEUROLEPTIC AGENT; OLANZAPINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROATE SEMISODIUM; ZIPRASIDONE;

BORDERLINE STATE; COGNITION; DRUG EFFICACY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; CLINICAL TRIALS AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80052438967     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31822c1636     Document Type: Review

References (69)

1. Kernberg OF, Michels R. Borderline personality disorder. Am J Psychiatry. 2009;166:505-508.
2. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Borderline Personality Disorder. Washington, DC: American Psychiatric Association; 2001.
3. Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis I comorbidity of borderline personality disorder. Am J Psychiatry. 1998;155: 1733-1739. (Pubitemid 28547499)
4. Walter M, Gunderson JC, Zanarini MC, et al. New onset of substance abuse disorders in borderline personality disorder over 7 years of follow-up: findings from the Collaborative Longitudinal Personality Disorders Study. Addiction. 2009;104:97-103.
5. Oldham JM. Borderline personality disorder and suicidality. Am J Psychiatry. 2006;163:20-26. (Pubitemid 43050098)
6. Bender DS, Dolan RT, Skodol AE, et al. Treatment utilization by patients with personality disorders. Am J Psychiatry. 2001;158:295-302. (Pubitemid 32116528)
7. Zanarini MC, Frankenburg FR, Khera GS, et al. Treatment histories of borderline inpatients. Compr Psychiatry. 2001;42:144-150. (Pubitemid 32207250)
8. Zanarini MC, Frankenburg FR, Hennen J, et al. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry. 2003;160:274-283. (Pubitemid 41110452)
9. Zanarini MC. Update on pharmacotherapy of borderline personality disorder. Curr Psychiatry Rep. 2004;6:66-70. (Pubitemid 38899254)
10. Oldham JM. Practice Guideline for the Treatment of Patients with Borderline Personality Disorder. Arlington, VA: American Psychiatric Association; 2005.
11. Lieb K, Zanarini MC, Schmahl C, et al. Borderline personality disorder. Lancet. 2004;364:453-461. (Pubitemid 39036894)
12. Binks CA, Fenton M, McCarthy L, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2006;(1):CD005653.
13. Nosè M, Cipriani A, Biancosino B, et al. Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2006;21: 345-353. (Pubitemid 44498276)
14. Herpertz SC, Zanarini M, Schulz CS, et al. WFSBP Task Force on Personality Disorders; World Federation of Societies of Biological Psychiatry (WFSBP). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry. 2007;8:212-244. (Pubitemid 350018476)
15. Mercer D, Douglass AB, Links PS. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. J Pers Disord. 2009;23:156-174.
16. Lieb K, Völlm B, Rücker G, et al. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010;196:4-12.
17. Ingenhoven T, Lafay P, Rinne T, et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010;71:14-25.
18. National Collaborating Centre for Mental Health. Borderline Personality Disorder: Treatment and Management. Full Guideline. Clinical Guideline 78. NICE, 2009 (http://www.nice.org.uk/nicemedia/pdf/CG78FullGuideline.pdf).
19. Furokawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol. 2006;59:7-10. (Pubitemid 41797469)
20. Hedges LV, Holkin I. Statistical Methods for Meta-Analysis. New York, NY: Academic Press; 1985.
21. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634. (Pubitemid 27387172)
22. Bogenschutz MP, Nurnberg GH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104-109.
23. Pascual JC, Soler J, Puigdemont D, et al. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008;69:603-608. (Pubitemid 351792335)
24. Schulz SC, Zanarini MC, Bateman A, et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008;193: 485-492.
25. Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163:833-838. (Pubitemid 44464531)
26. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45:111-119. (Pubitemid 18052841)
27. Hollander E, Allen A, Prieto Lopez R, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001;62:199-203. (Pubitemid 32270095)
28. Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol. 2009;24: 270-275.
29. Nickel M, Nickel C. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004;65:1515-1519.
30. Nickel M. Treatment of aggression with topiramate in male borderline patients. A double-blind, placebo-controlled study. Biol Psychiatry. 2005;57:495-499. (Pubitemid 40311984)
31. Tritt K, Nickel C, Lahmann C. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005;19:287-291. (Pubitemid 40694947)
32. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry. 1997;54: 1081-1088. (Pubitemid 27524373)
33. Rinne T, van den Brink W. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with BPD. Am J Psychiatry. 2002;159:2048-2054. (Pubitemid 35423864)
34. Simpson EB, Yen S, Costello E, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:379-385.
35. Salzman C, Wolsfon A, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995;15:23-29.
36. Soloff PH, George A, Nathan RS, et al. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry. 1986;43:691-697. (Pubitemid 16094181)
37. Soloff PH, Cornelius JR, George A. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993;50:377-385. (Pubitemid 23143127)
38. Soler J, Pascual JC, Campins J. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162:1221-1224. (Pubitemid 40770712)
39. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003;28:1186-1197.
40. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002;63:442-446. (Pubitemid 34507223)
41. Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry. 2003;64:628-634. (Pubitemid 36750138)
42. Goldberg SC, Schulz SC, Schulz PM, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry. 1986;43:680-686. (Pubitemid 16094180)
43. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62:849-854. (Pubitemid 33131170)
44. Linehan MM, McDavid JD, Brown MZ, et al. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69: 999-1005. (Pubitemid 351944956)
45. de la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol. 1994;4:479-486.
46. Loew TH, Nickel MK, Muehlbacher M, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006;26:61-66. (Pubitemid 43167093)
47. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. 2006;67:1042-1046. (Pubitemid 44230874)
48. Benedetti F, Sforzini L, Colombo C, et al. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry. 1998;59:103-107. (Pubitemid 28150854)
49. Teicher MH, Glod CA, Aaronson ST, et al. Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. Psychopharmacol Bull. 1989;25:535-549. (Pubitemid 20137978)
50. Van den Eynde F, Senturk V, Naudts K, et al. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol. 2008;28:147-155. (Pubitemid 351417119)
51. Stein D, Simeon D, Frenkel M, et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry. 1995;56:506-510.
52. Kavoussi R, Coccaro E. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry. 1998;59:676-680. (Pubitemid 29068313)
53. Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. 2005;66:1111-1115. (Pubitemid 41442276)
54. Kutcher S, Papatheodorou G, Reiter S, et al. The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol. J Psychiatry Neurosci. 1995;20:113-118.
55. Schulz SC, Camlin KL, Berry SA, et al. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999;46:1429-1435.
56. Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as a target. J Clin Psychiatry. 2005;66:1298-1303. (Pubitemid 41546510)
57. Adityanjee A, Brown E, Thuras P. Quetiapine in patients with borderline personality disorder: an open-label trial. Ann Clin Psychiatry. 2008;20:219-226.
58. Roepke S, Merkl A, Dams A, et al. Preliminary evidence of improvement of depressive symptoms but not impulsivity in cluster B personality disorder patients treated with quetiapine: an open label trial. Pharmacopsychiatry. 2008;41:176-181.
59. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. Psychiatry Res. 2008;161:206-212.
60. Shoja-Shafti S. Treatment of borderline personality disorder with olanzapine. Arch Iranian Med. 2006;9:403-405. (Pubitemid 44803585)
61. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline personality disorder: a preliminary study. Compr Psychiatry. 1993;34:402-405. (Pubitemid 23358021)
62. Perrella C, Carrusa D, Costa E, et al. Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:158-163. (Pubitemid 44959269)
63. Rocca P, Marchiaro L, Cocuzza E, et al. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry. 2002;63:241-244. (Pubitemid 34407084)
64. Chengappa KN, Ebeling T, Kang SJ. Clozapine reduces severe self mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry. 1999;60:477-484. (Pubitemid 29369804)
65. Bellino S, Paradiso E, Bozzatello P, et al. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. J Psychopharmacol. 2010;24:333-339.
66. Kavoussi RJ, Liu J, Coccaro EF. An open trial of sertraline in borderline personality disordered patients with impulsive aggression. J Clin Psychiatry. 1994;55:137-141. (Pubitemid 24143118)
67. Markowitz PJ, Calabrese JR, Schulz SC, et al. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry. 1991;148:1064-1067.
68. Markowitz PJ, Wagner S. Venlafaxine in the treatment of borderline personality disorders. Psychopharmacol Bull. 1995;31:773-777. (Pubitemid 26091746)
69. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.